[go: up one dir, main page]

WO2015169945A3 - Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) - Google Patents

Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) Download PDF

Info

Publication number
WO2015169945A3
WO2015169945A3 PCT/EP2015/060168 EP2015060168W WO2015169945A3 WO 2015169945 A3 WO2015169945 A3 WO 2015169945A3 EP 2015060168 W EP2015060168 W EP 2015060168W WO 2015169945 A3 WO2015169945 A3 WO 2015169945A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
tumor
relates
aml
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/060168
Other languages
English (en)
Other versions
WO2015169945A2 (fr
Inventor
Juliane STICKEL
Daniel Kowalewski
Claudia BERLIN
Hans-Georg Rammensee
Stefan Stevanovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2015257652A priority Critical patent/AU2015257652B2/en
Priority to DK15732544.0T priority patent/DK3140319T3/da
Priority to EP19185183.1A priority patent/EP3604327A1/fr
Priority to MX2016014711A priority patent/MX2016014711A/es
Priority to SI201530901T priority patent/SI3140319T1/sl
Priority to PL15732544T priority patent/PL3140319T3/pl
Priority to LTEP15732544.0T priority patent/LT3140319T/lt
Priority to CR20160531A priority patent/CR20160531A/es
Priority to JP2016567242A priority patent/JP6659582B2/ja
Priority to MA39907A priority patent/MA39907B1/fr
Priority to MEP-2019-258A priority patent/ME03565B/fr
Priority to CN201580022755.4A priority patent/CN106459167A/zh
Priority to EP18193811.9A priority patent/EP3449937A1/fr
Priority to ES15732544T priority patent/ES2747734T3/es
Priority to RS20191183A priority patent/RS59471B1/sr
Priority to CA2946349A priority patent/CA2946349A1/fr
Priority to HRP20191671 priority patent/HRP20191671T1/hr
Priority to HK17105901.8A priority patent/HK1232240B/en
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to KR1020167034386A priority patent/KR20170003976A/ko
Priority to SG11201608332SA priority patent/SG11201608332SA/en
Priority to EP15732544.0A priority patent/EP3140319B1/fr
Priority to BR112016025035A priority patent/BR112016025035A2/pt
Priority to EA201692103A priority patent/EA035456B1/ru
Publication of WO2015169945A2 publication Critical patent/WO2015169945A2/fr
Publication of WO2015169945A3 publication Critical patent/WO2015169945A3/fr
Priority to IL248203A priority patent/IL248203A0/en
Priority to PH12016502008A priority patent/PH12016502008A1/en
Anticipated expiration legal-status Critical
Priority to CY20191101007T priority patent/CY1122083T1/el
Priority to IL271367A priority patent/IL271367A/en
Priority to AU2020200066A priority patent/AU2020200066A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04004—Plus-end-directed kinesin ATPase (3.6.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y599/00—Other isomerases (5.99)
    • C12Y599/01—Other isomerases (5.99.1)
    • C12Y599/01002—DNA topoisomerase (5.99.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La présente invention concerne des peptides, des acides nucléiques et des cellules pour leur utilisation dans des méthodes immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie du cancer. La présente invention concerne en outre des épitopes peptidiques des lymphocytes T cytotoxiques (LTC) associés à une tumeur, seuls ou en combinaison avec d'autres peptides associés à une tumeur qui servent d'ingrédients pharmaceutiques actifs de compositions vaccinales qui stimulent des réponses immunitaires anti-tumorales. La présente invention concerne plusieurs nouvelles séquences peptidiques et leurs variants dérivés de molécules HLA de classe I et des molécules HLA de classe II de cellules tumorales humaines qui peuvent être utilisées dans des compositions vaccinales pour induire des réponses immunitaires antitumorales.
PCT/EP2015/060168 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) Ceased WO2015169945A2 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
HRP20191671 HRP20191671T1 (hr) 2014-05-09 2015-05-08 Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
EP19185183.1A EP3604327A1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
MX2016014711A MX2016014711A (es) 2014-05-09 2015-05-08 Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
SI201530901T SI3140319T1 (sl) 2014-05-09 2015-05-08 Nova imunoterapija proti različnim tumorjem krvi, kot akutni mieloični levkemiji (AML)
PL15732544T PL3140319T3 (pl) 2014-05-09 2015-05-08 Nowa immunoterapia przeciwko szeregowi nowotworów krwi, takich jak ostra białaczka szpikowa (AML)
LTEP15732544.0T LT3140319T (lt) 2014-05-09 2015-05-08 Nauja imunoterapija prieš tam tikrus kraujo navikus, tokius kaip ūminė mielogeninė leukemija (aml)
CR20160531A CR20160531A (es) 2014-05-09 2015-05-08 Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
JP2016567242A JP6659582B2 (ja) 2014-05-09 2015-05-08 急性骨髄性白血病（ａｍｌ）などの血液のいくつかの腫瘍に対する新規免疫療法
MA39907A MA39907B1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
MEP-2019-258A ME03565B (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
CN201580022755.4A CN106459167A (zh) 2014-05-09 2015-05-08 急性骨髓性白血病(aml)等几种血液肿瘤的新型免疫疗法
EP18193811.9A EP3449937A1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
ES15732544T ES2747734T3 (es) 2014-05-09 2015-05-08 Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (LMA)
RS20191183A RS59471B1 (sr) 2014-05-09 2015-05-08 Nova imunoterapija za lečenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
CA2946349A CA2946349A1 (fr) 2014-05-09 2015-05-08 Nouvelle immunotherapie contre plusieurs tumeurs, du sang, notamment la leucemie aigue myeloide (lam)
AU2015257652A AU2015257652B2 (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
DK15732544.0T DK3140319T3 (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
HK17105901.8A HK1232240B (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
KR1020167034386A KR20170003976A (ko) 2014-05-09 2015-05-08 급성 골수성 백혈병(aml)과 같은 여러 혈액 종양에 대한 신규 면역요법
SG11201608332SA SG11201608332SA (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
EP15732544.0A EP3140319B1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
BR112016025035A BR112016025035A2 (pt) 2014-05-09 2015-05-08 imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
EA201692103A EA035456B1 (ru) 2014-05-09 2015-05-08 Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл)
IL248203A IL248203A0 (en) 2014-05-09 2016-10-06 Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
PH12016502008A PH12016502008A1 (en) 2014-05-09 2016-10-10 Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
CY20191101007T CY1122083T1 (el) 2014-05-09 2019-09-24 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ)
IL271367A IL271367A (en) 2014-05-09 2019-12-11 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
AU2020200066A AU2020200066A1 (en) 2014-05-09 2020-01-04 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990980P 2014-05-09 2014-05-09
GB1408255.6 2014-05-09
GBGB1408255.6A GB201408255D0 (en) 2014-05-09 2014-05-09 Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
US61/990,980 2014-05-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP18193811.9A Previously-Filed-Application EP3449937A1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
EP19185183.1A Previously-Filed-Application EP3604327A1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)

Publications (2)

Publication Number Publication Date
WO2015169945A2 WO2015169945A2 (fr) 2015-11-12
WO2015169945A3 true WO2015169945A3 (fr) 2016-02-04

Family

ID=51032516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/060168 Ceased WO2015169945A2 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)

Country Status (25)

Country Link
US (2) US10064924B2 (fr)
EP (3) EP3449937A1 (fr)
JP (1) JP6659582B2 (fr)
KR (1) KR20170003976A (fr)
CN (1) CN106459167A (fr)
AU (2) AU2015257652B2 (fr)
BR (1) BR112016025035A2 (fr)
CA (1) CA2946349A1 (fr)
CR (1) CR20160531A (fr)
DK (1) DK3140319T3 (fr)
EA (2) EA202090751A3 (fr)
ES (1) ES2747734T3 (fr)
GB (1) GB201408255D0 (fr)
HU (1) HUE045177T2 (fr)
LT (1) LT3140319T (fr)
MA (3) MA49287A (fr)
ME (1) ME03565B (fr)
MX (1) MX2016014711A (fr)
PL (1) PL3140319T3 (fr)
PT (1) PT3140319T (fr)
RS (1) RS59471B1 (fr)
SG (1) SG11201608332SA (fr)
SI (1) SI3140319T1 (fr)
TW (2) TW201920246A (fr)
WO (1) WO2015169945A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10000533B2 (en) * 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
CA2984643A1 (fr) 2015-05-13 2016-11-17 Agenus Inc. Vaccins pour le traitement et la prevention du cancer
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US10357550B2 (en) 2016-04-06 2019-07-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers
KR102411975B1 (ko) 2016-04-06 2022-06-22 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
WO2017177178A1 (fr) * 2016-04-07 2017-10-12 Case Western Reserve University Inhibiteur de la localisation mitochondriale de tdp -43 pour le traitement d'une maladie neurodégénérative
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3034124A1 (fr) * 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Peptides de fusion avec des antigenes lies a des fragments courts de chaine invariante (cd74)
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CN112521478A (zh) 2017-04-10 2021-03-19 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
EP3609522A4 (fr) * 2017-04-10 2021-05-05 Yoram Palti Méthodes et composés pour le traitement du diabète
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
CA3083242A1 (fr) * 2017-11-21 2019-05-31 Naofumi MIWA Agent inhibiteur de metastases de cellules cancereuses humaines et agent de determination de cellules cancereuses humaines
CA3083097A1 (fr) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reduction de la presentation d'epitope de jonction pour des neo-antigenes
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN108707666B (zh) * 2018-05-28 2021-04-09 陕西中医药大学第二附属医院 Dgkz基因作为白血病检测的生物标志物的应用
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
WO2020180713A1 (fr) * 2019-03-01 2020-09-10 Flow Pharma, Inc. Conception, fabrication et utilisation de vaccins anticancéreux personnalisés
CN112409449B (zh) * 2019-08-19 2023-12-15 辽宁中健医药科技有限公司 Hla-a0201限定性kif15特异性抗肿瘤ctl优势表位肽及应用
CN115397842A (zh) * 2020-04-14 2022-11-25 蒙特利尔大学 用于急性髓系白血病(aml)的新型肿瘤特异性抗原及其用途
CN112980955A (zh) * 2021-03-05 2021-06-18 南昌大学第二附属医院 Emilin2作为胶质瘤替莫唑胺耐药检测、治疗及预后分子靶点的应用
CN113130001B (zh) * 2021-03-31 2023-07-18 甘肃中医药大学 一种天然化合物与抗肿瘤化合物配伍的筛选方法
EP4334332A4 (fr) * 2021-05-04 2025-11-12 California Inst Of Techn Vaa recombinants pour administration au système nerveux central et à la vasculature cérébrale
EP4392441A1 (fr) * 2021-08-24 2024-07-03 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
CN114703274B (zh) * 2022-04-01 2023-08-15 中国人民解放军总医院 Phpt1在预警和/或治疗高原病中的应用
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2025011658A1 (fr) * 2023-07-12 2025-01-16 Anda Biology Medicine Development (Shenzhen) Co., Ltd Nouveaux marqueurs pour vaccins à néo-antigènes tumoraux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040101707A (ko) * 2003-05-26 2004-12-03 학교법인 배재학당 Ｆａｆ1 단편 및 그를 함유하는 종양 전이 억제제
US20050261190A1 (en) * 2004-04-29 2005-11-24 Sk Corp. Fas associated factor 1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt) 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7033400A (en) * 1999-08-30 2001-03-26 Jehad Mikhaiel Charo Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65
ES2337429T3 (es) * 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
WO2001041787A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
WO2001070955A2 (fr) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification de genes esentiels dans des procaryotes
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2404489A1 (fr) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
EP2322228B1 (fr) 2000-06-05 2018-01-10 Altor BioScience Corporation Protéines de fusion et conjugués de récepteurs de lymphocytes T et procédés d'utilisation de ceux-ci
WO2003057823A2 (fr) * 2001-11-07 2003-07-17 Mannkind Corporation Synchronisation d'epitope dans les cellules qui presentent des antigenes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (fr) 2002-02-20 2006-04-26 Dyax Corp Ligands de liaison au complexe mhc-peptide
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
CA2505558C (fr) 2002-11-09 2013-07-02 Avidex Limited Presentation de recepteurs pour l'antigene des lymphocytes t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
HUE027164T2 (en) * 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
PL2113253T3 (pl) 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
KR101224466B1 (ko) * 2010-05-20 2013-01-22 가톨릭대학교 산학협력단 토포아이소머라아제 2 알파 유래의 종양항원 단백질, 유전자, 또는 펩타이드
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040101707A (ko) * 2003-05-26 2004-12-03 학교법인 배재학당 Ｆａｆ1 단편 및 그를 함유하는 종양 전이 억제제
US20050261190A1 (en) * 2004-04-29 2005-11-24 Sk Corp. Fas associated factor 1

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
C BERLIN ET AL: "Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy", LEUKEMIA, vol. 29, no. 3, 5 August 2014 (2014-08-05), pages 647 - 659, XP055207425, ISSN: 0887-6924, DOI: 10.1038/leu.2014.233 *
C. HASSAN ET AL: "The Human Leukocyte Antigen-presented Ligandome of B Lymphocytes", MOLECULAR & CELLULAR PROTEOMICS, vol. 12, no. 7, 1 July 2013 (2013-07-01), pages 1829 - 1843, XP055212020, ISSN: 1535-9476, DOI: 10.1074/mcp.M112.024810 *
DATABASE REFSEQ [online] GENBANK; 22 July 2014 (2014-07-22), NN: "FAS-associated factor 1-like, partial (Galeopterus variegatus)", XP002744356, accession no. XP_008593192 Database accession no. XP_008593192 *
DATABASE UniProt [online] 16 October 2013 (2013-10-16), "SubName: Full=Uncharacterized protein {ECO:0000313|EMBL:EPY84515.1};", XP002744426, retrieved from EBI accession no. UNIPROT:S9YKJ2 Database accession no. S9YKJ2 *
GREINER JOCHEN ET AL: "Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.", HAEMATOLOGICA, vol. 91, no. 12, December 2006 (2006-12-01), pages 1653 - 1661, XP002744391, ISSN: 1592-8721 *
HANS-GEORG RAMMENSEE ET AL: "HLA ligandome tumor antigen discovery for personalized vaccine approach", EXPERT REVIEW OF VACCINES, vol. 12, no. 10, 1 October 2013 (2013-10-01), pages 1211 - 1217, XP055144265, ISSN: 1476-0584, DOI: 10.1586/14760584.2013.836911 *
NORIMITSU KADOWAKI ET AL: "Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 163, no. 10, 1 January 2011 (2011-01-01), pages 5211 - 7, XP055212173, ISSN: 1740-2522, DOI: 10.1182/blood-2009-11-249474 *
OSTANKOVITCH MARINA ET AL: "Antileukemia HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts", BLOOD, vol. 92, no. 1, 1 July 1998 (1998-07-01), pages 19 - 24, XP002744389, ISSN: 0006-4971 *
SCHMITT MICHAEL ET AL: "Peptide vaccines for patients with acute myeloid leukemia.", October 2009 (2009-10-01), XP002744390, Retrieved from the Internet <URL:http://www.medscape.com/viewarticle/710604_print> [retrieved on 20150909] *
SEBASTIAN P HAEN ET AL: "The repertoire of human tumor-associated epitopes - identification and selection of antigens and their application in clinical trials", CURRENT OPINION IN IMMUNOLOGY, vol. 25, no. 2, 1 April 2013 (2013-04-01), pages 277 - 283, XP055212257, ISSN: 0952-7915, DOI: 10.1016/j.coi.2013.03.007 *
STICKEL JULIANE S ET AL.: "HLA class I ligandome analysis in Acute Myeloid Leukemia-Novel-T-Cell epitopes for peptide-based immunotherapy", vol. 122, no. 21, 15 November 2013 (2013-11-15), XP002744388, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/122/21/5431.full.pdf> [retrieved on 20150908] *

Also Published As

Publication number Publication date
US10064924B2 (en) 2018-09-04
HUE045177T2 (hu) 2019-12-30
PL3140319T3 (pl) 2020-02-28
MA39907B1 (fr) 2019-09-30
CA2946349A1 (fr) 2015-11-12
MA49287A (fr) 2020-02-05
SG11201608332SA (en) 2016-11-29
TW201625676A (zh) 2016-07-16
EP3449937A1 (fr) 2019-03-06
AU2020200066A1 (en) 2020-01-30
US20150320848A1 (en) 2015-11-12
JP2017524337A (ja) 2017-08-31
BR112016025035A2 (pt) 2017-10-24
DK3140319T3 (en) 2019-09-23
EA201692103A1 (ru) 2017-04-28
RS59471B1 (sr) 2019-12-31
EA202090751A2 (ru) 2020-07-31
SI3140319T1 (sl) 2019-11-29
EP3604327A1 (fr) 2020-02-05
TWI668230B (zh) 2019-08-11
AU2015257652B2 (en) 2019-10-10
EP3140319A2 (fr) 2017-03-15
TW201920246A (zh) 2019-06-01
CN106459167A (zh) 2017-02-22
EA202090751A3 (ru) 2020-10-30
LT3140319T (lt) 2019-09-25
EA035456B1 (ru) 2020-06-18
WO2015169945A2 (fr) 2015-11-12
GB201408255D0 (en) 2014-06-25
AU2015257652A1 (en) 2016-09-29
MA39907A (fr) 2017-03-15
ME03565B (fr) 2020-07-20
MA49280A (fr) 2019-03-06
JP6659582B2 (ja) 2020-03-04
MX2016014711A (es) 2017-10-23
PT3140319T (pt) 2019-10-15
US20180311330A1 (en) 2018-11-01
US10286052B2 (en) 2019-05-14
ES2747734T3 (es) 2020-03-11
CR20160531A (es) 2017-04-27
EP3140319B1 (fr) 2019-07-10
KR20170003976A (ko) 2017-01-10

Similar Documents

Publication Publication Date Title
WO2015169945A3 (fr) Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
WO2015193359A3 (fr) Nouvelle immunothérapie dirigée contre plusieurs tumeurs du sang, en particulier la leucémie lymphoïde chronique (llc)
PH12019502194A1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2015063302A3 (fr) Immunothérapie personnalisée contre plusieurs tumeurs neuronales et cérébrales
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
PH12016502008A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
MY198397A (en) Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15732544

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015257652

Country of ref document: AU

Date of ref document: 20150508

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 248203

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12016502008

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2946349

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016025035

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016567242

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/014711

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: CR2016-000531

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 201692103

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2015732544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015732544

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167034386

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201611306

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112016025035

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161026